ZYME (Zymeworks Inc.) Market Value to Book Value Ratio

Zymeworks Inc. (ZYME) operates within the oncology sector, developing bispecific antibodies to combat severe tumors, where success depends on FDA verdicts. This price chart links the company's approach to alliances with industry behemoths to accelerate product commercialization. The current metric stands at 25.14, however, the business is burdened by fierce competition, costly research, and the potential for joint program failures.

Zymeworks Biopharmaceuticals (ZYME): Capitalization to Book Value Ratio from 07/04/2022 to 10/27/2026

Financial and market metric breakdowns for Zymeworks Inc (ZYME)

- price and consensus price forecast:

Stock Price Zymeworks Inc.|ZYME - Average Forecast Price

- market capitalization data:

Market Value Zymeworks Corp|ZYME - Total Enterprise Value

- book capitalization data:

Net Assets per Single Share Zymeworks|ZYME - Accounting Capitalization|Market Capitalization to Book Value Ratio zymeworks.com|ZYME - Cumulative Company Assets

- debt and liquidity data:

Debt to Equity Zymeworks Inc.|ZYME - Long-Term Liabilities to Capital|Short-Term Debt to Equity Zymeworks Corp|ZYME - Company Debts|Debt to Book Capitalization Ratio Zymeworks Corp

Fundamental valuation:Zymeworks Inc.

Zymeworks Inc. (ZYME) possesses high scientific potential in developing cancer therapy antibodies, which creates a significant premium over its net asset value. This market cap-to-book value ratio measures the market's revaluation of the business relative to its balance sheet, allowing investors to assess the degree of optimism priced into the quotes and the risk of correction when analyzing the price action on the chart.

Competitor analysis